Peptides for promoting angiogenesis and use thereof

Patent metadata

Field	Value
Publication number	US-2017166609-A1
Application number	US-201715434309-A
Country	US
Kind code	A1
Filing date	Feb 16, 2017
Priority date	Mar 26, 2010
Publication date	Jun 15, 2017
Grant date	—

Abstract

The present invention relates to a peptide promoting angiogenesis and novel use thereof. More particularly, the invention relates to peptides promoting angiogenesis, and the use of the peptide for promoting angiogenesis and preventing or treating angiogenesis-related disease. The peptide of the present invention have an excellent effect on promoting angiogenesis. Accordingly, it is useful for preventing or treating angiogenesis-related disease and for preparing regeneration of skin flap, wound and burn healing, implantation of artificial skin and preparation of blood vessels for transplantation.

First claim

1 - 13 . (canceled)

14 . An isolated peptide consisting of the amino acid sequence set forth in SEQ ID NO: 4.

15 . The isolated peptide of claim 14 , wherein the C-terminal end of the peptide is amidated.

16 . A composition comprising the isolated peptide of claim 14 .

17 . A composition comprising the isolated peptide of claim 15 .

18 . A method for promoting angiogenesis by administering an effective amount of the isolated peptide of claim 14 to a subject in need thereof.

19 . A method for treating an angiogenesis-related disease administering an effective amount of the isolated peptide of claim 14 to a subject in need thereof, wherein the angiogenesis-related disease is selected from a group consisting of diabetic foot ulcer, pulmonary hypertension, ischemic cardiomyopathy, ischemic brain disease, heart failure, acute posterior ischemia, bedsore, chronic ulcer, baldness or hair graying, obesity-related cardiovascular disease, and ischemia.

20 . A method for promoting angiogenesis by administering an effective amount of the isolated peptide of claim 15 to a subject in need thereof.

21 . A method for treating an angiogenesis-related disease administering an effective amount of the isolated peptide of claim 15 to a subject in need thereof, wherein the angiogenesis-related disease is selected from a group consisting of diabetic foot ulcer, pulmonary hypertension, ischemic cardiomyopathy, ischemic brain disease, heart failure, acute posterior ischemia, bedsore, chronic ulcer, baldness or hair graying, obesity-related cardiovascular disease, and ischemia.

Assignees

• Industry-Academic Coop Found Sookmyung Women'S Univ
• Il-Yang Pharm Co Ltd
• Samsung Life Public Welfare Foundation

Inventors

• Cho Dae Ho
• Bang Sa Ik
• Park Jeong Min
• Yoon Sun Young
• Kim Sang Yoon
• Lee Ha Rum
• Park Yoo Rim
• Son Juah

Classifications

• A61P9/04

  Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P9/12

  Antihypertensives · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P27/06

  Antiglaucoma agents or miotics · CPC title